Scott T. Tagawa, MD, MS

Articles

Overview of Treatment for Metastatic HSPC

April 20th 2022

Expert perspectives on metastatic hormone-sensitive prostate cancer and the current state of the treatment armamentarium.

Monitoring Strategies in Nonmetastatic CRPC

April 13th 2022

A brief discussion on best practices in monitoring patients on therapy for nonmetastatic castration-resistant prostate cancer [nmCRPC].

Phenotypic Biomarkers in the Management of Prostate Cancer

April 6th 2022

Expert perspectives on phenotypic biomarkers in prostate cancer and their role in comparison to genotypic biomarkers.

Factors in Selecting Novel AR-Targeted Therapy for Nonmetastatic CRPC

April 6th 2022

Comprehensive insight on selecting androgen receptor–targeted therapy for patients with nonmetastatic castration-resistant prostate cancer.

Background on Prostate Cancer and Biomarker Testing

April 6th 2022

Broad discussion on the role of biomarker testing in prostate cancer, particularly how it has helped to inform therapy selection and patient management.

Evolving Treatment Landscape of Nonmetastatic CRPC

April 6th 2022

Focusing on nonmetastatic castration-resistant prostate cancer, panelists review the current treatment armamentarium and shared decisionmaking.

Future Outlook on the Management of Metastatic Urothelial Cancer

December 15th 2021

Drs Arlene O. Siefker-Radtke and Scott T. Tagawa consider how the urology field will likely advance with more interest in genomic profiling in metastatic urothelial cancer and novel therapies in the pipeline.

Mitigating FGFR Inhibitor TRAEs in Metastatic Urothelial Cancer

December 15th 2021

An overview of adverse events commonly associated with FGFR-targeted therapies such as erdafitinib.

FGFR-Targeted Therapy for Metastatic Urothelial Cancer

December 6th 2021

Strategies that can be used to counsel patients on molecular testing for FGFR mutations and what to expect from treatment with erdafitinib.

Repeat Molecular Testing in Metastatic Urothelial Cancer

December 6th 2021

Current recommendations for repeat testing in patients with relapsed metastatic urothelial cancer.

Frontline Therapy for Metastatic Urothelial Cancer

December 1st 2021

Factors that impact the selection of immunotherapy vs chemotherapy for frontline metastatic urothelial cancer.

Treatment Planning for a Patient With Metastatic Urothelial Cancer

December 1st 2021

Drs Arlene O. Siefker-Radtke and Scott T. Tagawa explain how they would establish goals of therapy and a treatment algorithm for a patient who presents with metastatic urothelial cancer.

Antibody-Drug Conjugates Carve Out Space in Urothelial Carcinoma Landscape

November 12th 2020

Monoclonal antibodies have played a key role in the development of personalized oncology and have proven antitumor activity through multiple mechanisms, including direct transmembrane signaling leading to apoptosis, complement mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and inhibiting tumor vasculature and stroma.

Dr. Tagawa on Ongoing Research With 225Ac-J591 in mCRPC

April 17th 2020

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, and associate attending physician, Weill Cornell Medical Center/NewYork-Presbyterian Hospital, discusses ongoing research with 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Tagawa on Targeting PSMA in Prostate Cancer

April 10th 2020

Scott T. Tagawa, MD, MS, discusses the utility of beta and alpha emitters in targeting PSMA in prostate cancer.

Dr. Tagawa on Remaining Questions With PSMA-Targeted Radionuclide Therapy in mCRPC

March 28th 2020

Scott T. Tagawa, MD, MS, discusses remaining questions regarding treatment selection and PSMA imaging in metastatic castration-resistant prostate cancer.

Dr. Tagawa on Safety Profile of 225Ac-J591 in mCRPC

March 27th 2020

Scott T. Tagawa, MD, MS, discusses the safety profile of novel monoclonal antibody 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Tagawa on Preliminary Data With 225Ac-J591 in mCRPC

February 25th 2020

Scott T. Tagawa, MD, MS, discusses preliminary data with 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Tagawa Discusses the Development of Immunotherapy in Urothelial Cancer

April 14th 2017

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the development of immunotherapy for patients with urothelial cancer.